Medpage Today on MSN
Meta-Analyses Argue for Broader Use of SGLT2 Inhibitors in Chronic Kidney Disease
The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
Combining oral upadacitinib and topical ruxolitinib cream showed superior repigmentation outcomes in progressive nonsegmental vitiligo compared to monotherapies. Significant improvements were observed ...
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation of treatment for both metastatic castration-sensitive prostate cancer ...
Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...
The MARIPOSA trial demonstrates that amivantamab plus lazertinib significantly reduces resistance and extends survival in EGFR-mutated NSCLC compared to osimertinib. Dual inhibition of EGFR and MET by ...
TipRanks on MSN
Aprea Therapeutics Reports Q3 Results and Clinical Updates
The latest announcement is out from Aprea Therapeutics ( (APRE) ).
Whether a person eats a cookie or devours the whole box could come down to the mood of microglia in their hypothalamus. Blocking activation of the region’s NLRP3 inflammasome could keep excessive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback